CARM - Carisma Therapeutics Inc.

QQQ $ 442.43 $ -0.49 (-0.11 %)

DIA $ 394.43 $ 3.52 (0.9 %)

SPY $ 521.52 $ 0.00 (0 %)

TLT $ 90.31 $ 0.00 (0 %)

GLD $ 218.88 $ -0.90 (-0.41 %)

Previous Close

$ 1.51

Open

$ 1.48

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 1.48 - $ 1.52

52 Week Range

$ 1.47 - $ 9.77

Volume

185,533

Average Volume

Market Cap

61.82M

Beta (5Y Monthly)

$ 0.04

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	05-09-2024	03-31-2024	10-Q
2	04-01-2024	12-31-2023	10-K
3	11-09-2023	09-30-2023	10-Q
4	08-10-2023	06-30-2023	10-Q
5	05-11-2023	03-31-2023	10-Q
6	02-28-2023	12-31-2022	10-K
7	11-07-2022	09-30-2022	10-Q
8	08-08-2022	06-30-2022	10-Q
9	05-09-2022	03-31-2022	10-Q
10	02-28-2022	12-31-2021	10-K
11	11-08-2021	09-30-2021	10-Q
12	08-09-2021	06-30-2021	10-Q
13	05-10-2021	03-31-2021	10-Q
14	03-15-2021	12-31-2020	10-K
15	11-09-2020	09-30-2020	10-Q
16	08-10-2020	06-30-2020	10-Q
17	05-11-2020	03-31-2020	10-Q
18	03-16-2020	12-31-2019	10-K
19	11-12-2019	09-30-2019	10-Q
20	08-08-2019	06-30-2019	10-Q
21	05-10-2019	03-31-2019	10-Q
22	03-01-2019	12-31-2018	10-K
23	11-09-2018	09-30-2018	10-Q
24	08-14-2018	06-30-2018	10-Q
25	05-15-2018	03-31-2018	10-Q
26	04-02-2018	12-31-2017	10-K
27	11-17-2017	09-30-2017	10-Q
28	08-14-2017	06-30-2017	10-Q
29	05-04-2017	03-31-2017	10-Q
30	03-24-2017	12-31-2016	10-K
31	11-14-2016	09-30-2016	10-Q
32	08-12-2016	06-30-2016	10-Q
33	05-05-2016	03-31-2016	10-Q
34	03-25-2016	12-31-2015	10-K
35	11-04-2015	09-30-2015	10-Q
36	08-13-2015	06-30-2015	10-Q
37	04-30-2015	03-31-2015	10-Q
38	03-06-2015	12-31-2014	10-K
39	11-13-2014	09-30-2014	10-Q
40	08-13-2014	06-30-2014	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

HC Wainwright & Co. Maintains Buy on CARIS...
05/10/2024 11:46:46

HC Wainwright & Co. analyst Mitchell Kapoor maintains CARISMA Therapeutics (NASDAQ:CARM) with a Buy and lowers the price...

Carisma Therapeutics Says Cash And Equival...
05/09/2024 11:50:33

CARISMA Therapeutics Q1 2024 GAAP EPS $(0....
05/09/2024 11:49:45

CARISMA Therapeutics (NASDAQ:CARM) reported quarterly losses of $(0.46) per share which missed the analyst consensus estimate o...

Carisma Therapeutics Announced New Data De...
05/08/2024 11:47:54

Carisma Therapeutics To Present New Data A...
04/22/2024 20:42:13

Preclinical data highlights the potential of engineered macrophage cell therapy as a treatment for liver and lung fibrosisNovel...

BTIG Initiates Coverage On CARISMA Therape...
04/11/2024 16:19:24

BTIG analyst Justin Zelin initiates coverage on CARISMA Therapeutics (NASDAQ:CARM) with a Buy rating and announces Price Tar...

HC Wainwright & Co. Maintains Buy on CARIS...
04/02/2024 12:51:54

HC Wainwright & Co. analyst Mitchell Kapoor maintains CARISMA Therapeutics (NASDAQ:CARM) with a Buy and lowers the price...

CARISMA Therapeutics Q4 EPS $(0.52) Beats ...
04/01/2024 14:05:13

CARISMA Therapeutics (NASDAQ:CARM) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of ...

12-health-care-stocks-moving-in-wednesdays-after-market-session

12 Health Care Stocks Moving In Wednesday'...
01/10/2024 21:31:09

Carisma Therapeutics Has Nominated Its Fir...
12/14/2023 12:37:30

HC Wainwright & Co. Reiterates Buy on CARI...
11/29/2023 11:28:12

HC Wainwright & Co. analyst Mitchell Kapoor reiterates CARISMA Therapeutics (NASDAQ:CARM) with a Buy and maintains $11 p...

Carisma Therapeutics Secures FDA Clearance...
11/28/2023 12:05:38

Carisma expects to initiate a Phase 1 study in the coming months and to treat the first patient in the first half of 2024.

CARISMA Therapeutics' Q3 Cash, Cash Equiva...
11/09/2023 12:58:27

CARISMA Therapeutics Q3 EPS $(0.53) Beats ...
11/09/2023 12:57:44

CARISMA Therapeutics (NASDAQ:CARM) reported quarterly losses of $(0.53) per share which beat the analyst consensus estimate of ...

Benzinga's Top Ratings Upgrades, Downgrade...
10/03/2023 15:00:54

The Latest Analyst Ratings for CARISMA The...
10/03/2023 15:00:43

Capital One Initiates Coverage On CARISMA ...
10/03/2023 14:17:17

Capital One analyst Naureen Quibria initiates coverage on CARISMA Therapeutics (NASDAQ:CARM) with a Overweight rating and an...

What 5 Analyst Ratings Have To Say About C...
09/06/2023 14:00:37

HC Wainwright & Co. Reiterates Buy on CARI...
09/06/2023 10:25:09

HC Wainwright & Co. analyst Mitchell Kapoor reiterates CARISMA Therapeutics (NASDAQ:CARM) with a Buy and maintains $11 p...

Carisma Announces Latest Data From Phase 1...
09/01/2023 12:34:27

Group 2 data available to date support primary safety and feasibility endpoints of single-day bolus dosing of CT-0508 New tr...